Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Autologous Anti-LGR5 CAR-T Cells CNA3103

A preparation of autologous T-lymphocytes transduced to express a chimeric antigen receptor (CAR) targeting the cancer stem cell (CSC) marker leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-LGR5 CAR-T cells CNA3103 selectively target, binds to and lyse LGR5-expressing tumor cells. LGR5, a member of the Wnt signaling pathway, is overexpressed on certain cancer cells; it plays a key role in CSC proliferation and survival, tumor initiation, growth, and metastasis. Its expression is linked to poor survival and poor patient response to therapy. CNA3103 contains the antigen-biding domain of the humanized monoclonal LGR5 antibody BNC101.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:leucine-rich repeat-containing G protein-coupled receptor 5-targeted autologous CAR T cells CNA3103
leucine-rich repeat-containing G protein-coupled receptor 5-targeted autologous CAR T cells CNA3103
Leucine-rich Repeat-containing G Protein-coupled Receptor 5-targeted Autologous CAR T-cells CNA3103
LGR5-targeted autologous CAR-T cells CNA3103
Code name:CAN 3103
CAN-3103
CAN3103
CNA 3103
CNA-3103
CNA3103
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search